Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer.
Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer.
复制标题
在诊断 HPV 阳性头颈癌之前检测循环肿瘤人乳头瘤病毒 DNA。
DOI：
10.1002/ijc.33996
复制
发表时间：
2022
影响因子：
6.4
通讯作者：
Sroussi,Herve
中科院分区：
文献类型：
--
作者：
Rettig,EleniM;Faden,DanielL;Sandhu,Shaiba;Wong,Kristine;Faquin,WilliamC;Warinner,Chloe;Stephens,Phil;Kumar,Sunil;Kuperwasser,Charlotte;Richmon,JeremyD;Uppaluri,Ravindra;Varvares,Mark;Sethi,Rosh;Hanna,GlennJ;Sroussi,Herve
人乳头瘤病毒（HPV），最常见的是HPV 16，引起越来越多的头颈部鳞状细胞癌（HNSCC），包括许多发达国家绝大多数的口咽鳞状细胞癌。HPV阳性HNSCC的循环生物标志物可能允许早期诊断，并有可能降低发病率和死亡率。该病例对照研究评估了在后来诊断为HPV阳性HNSCC的个体的诊断前血浆中是否可检测到循环肿瘤HPV DNA（ctHPVDNA）。病例是基于医院的研究生物库的参与者，在HNSCC诊断前≥6个月收集存档血浆，并提供存档肿瘤组织用于HPV检测。对照组是没有癌症或HPV相关诊断的生物库参与者，按性别、种族、年龄和血浆采集年份与病例匹配10：1。使用先前经验证的基于数字液滴PCR的检测方法检测血浆和肿瘤组织中的HPV DNA，该方法可定量肿瘤组织修饰病毒（TTMV）HPV DNA。纳入了12例中位年龄为68.5岁（范围：51 - 87岁）的HNSCC患者。10例（83.3%）有HPV 16 DNA阳性肿瘤。在10例HPV 16阳性肿瘤患者中的3例（30%）的诊断前血浆中检测到ctHPV 16 DNA，包括7例HPV 16阳性口咽肿瘤患者中的3例（43%）。血浆采集时间分别为癌症诊断前19个月、34个月和43个月。100例对照均未检出ctHPV 16 DNA。这是第一次报告ctHPV 16 DNA在HPV 16阳性HNSCC诊断前至少几年可检测到。进一步研究ctHPV 16 DNA作为HPV 16阳性HNSCC早期诊断的生物标志物是必要的。
Human papillomavirus (HPV), most commonly HPV16, causes a growing subset of head and neck squamous cell carcinomas (HNSCCs), including the overwhelming majority of oropharynx squamous cell carcinomas in many developed countries. Circulating biomarkers for HPV‐positive HNSCC may allow for earlier diagnosis, with potential to decrease morbidity and mortality. This case‐control study evaluated whether circulating tumor HPV DNA (ctHPVDNA) is detectable in prediagnostic plasma from individuals later diagnosed with HPV‐positive HNSCC. Cases were participants in a hospital‐based research biobank with archived plasma collected≥6 months before HNSCC diagnosis, and available archival tumor tissue for HPV testing. Controls were biobank participants without cancer or HPV‐related diagnoses, matched 10:1 to cases by sex, race, age and year of plasma collection. HPV DNA was detected in plasma and tumor tissue using a previously validated digital droplet PCR‐based assay that quantifies tumor‐tissue‐modified viral (TTMV) HPV DNA. Twelve HNSCC patients with median age of 68.5 years (range, 51‐87 years) were included. Ten (83.3%) had HPV16 DNA‐positive tumors. ctHPV16DNA was detected in prediagnostic plasma from 3 of 10 (30%) patients with HPV16‐positive tumors, including 3 of 7 (43%) patients with HPV16‐positive oropharynx tumors. The timing of the plasma collection was 19, 34 and 43 months before cancer diagnosis. None of the 100 matched controls had detectable ctHPV16DNA. This is the first report that ctHPV16 DNA is detectable at least several years before diagnosis of HPV16‐positive HNSCC for a subset of patients. Further investigation of ctHPV16DNA as a biomarker for early diagnosis of HPV16‐positive HNSCC is warranted.